Robotic brace maker Myomo Q3 revenue rises on record O&P growth

Reuters11-11

Robotic brace maker Myomo Q3 revenue rises on record O&P growth

Overview

Myomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&P) revenue
Company reiterates full-year revenue guidance of $40 mln to $42 mln
Operating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&D

Outlook

Myomo reiterates full-year revenue guidance of $40 mln to $42 mln
Company expects cost reduction projects to improve margins by Q3 2026

Result Drivers

RECORD O&P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&P) revenue in Q3, contributing to revenue growth
MYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagement
PATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.09
Q3 Net Income		-$3.70 mln
Q3 Adjusted EBITDA		-$2.70 mln
Q3 Gross Margin		63.80%
Q3 Operating Expenses		$10 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Press Release: ID:nBw9ps2k4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582388238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582388238","market":"us","top_or_hot":-1,"title":"Robotic brace maker Myomo Q3 revenue rises on record O&P growth","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Robotic brace maker Myomo Q3 revenue rises on record O&amp;P growth</title></head><body><p><span>Overview</span></p><ul><li><p>Myomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&amp;P) revenue</p></li><li><p>Company reiterates full-year revenue guidance of $40 mln to $42 mln</p></li><li><p>Operating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&amp;D</p></li></ul><p><span>Outlook</span></p><ul><li><p>Myomo reiterates full-year revenue guidance of $40 mln to $42 mln</p></li><li><p>Company expects cost reduction projects to improve margins by Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD O&amp;P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&amp;P) revenue in Q3, contributing to revenue growth</p></li><li><p>MYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagement</p></li><li><p>PATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>63.80%</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li></ul><p>Press Release: <span>ID:nBw9ps2k4a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Robotic brace maker Myomo Q3 revenue rises on record O&P growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRobotic brace maker Myomo Q3 revenue rises on record O&P growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Robotic brace maker Myomo Q3 revenue rises on record O&amp;P growth</title></head><body><p><span>Overview</span></p><ul><li><p>Myomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&amp;P) revenue</p></li><li><p>Company reiterates full-year revenue guidance of $40 mln to $42 mln</p></li><li><p>Operating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&amp;D</p></li></ul><p><span>Outlook</span></p><ul><li><p>Myomo reiterates full-year revenue guidance of $40 mln to $42 mln</p></li><li><p>Company expects cost reduction projects to improve margins by Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD O&amp;P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&amp;P) revenue in Q3, contributing to revenue growth</p></li><li><p>MYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagement</p></li><li><p>PATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>63.80%</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li></ul><p>Press Release: <span>ID:nBw9ps2k4a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYO","symbol_name":"Myomo Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM12B:1","article_id":"2582388238","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582388238","pubTimestamp":1762810255,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Robotic brace maker Myomo Q3 revenue rises on record O&P growthOverviewMyomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&P) revenueCompany","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYO":"Myomo Inc.","BK4082":"医疗保健设备"},"translate_title":"机器人支架制造商Myomo第三季度收入因创纪录的O&P增长而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYO":0.9},"content_text":"Robotic brace maker Myomo Q3 revenue rises on record O&P growthOverviewMyomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&P) revenueCompany reiterates full-year revenue guidance of $40 mln to $42 mlnOperating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&DOutlookMyomo reiterates full-year revenue guidance of $40 mln to $42 mlnCompany expects cost reduction projects to improve margins by Q3 2026Result DriversRECORD O&P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&P) revenue in Q3, contributing to revenue growthMYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagementPATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.09Q3 Net Income-$3.70 mlnQ3 Adjusted EBITDA-$2.70 mlnQ3 Gross Margin63.80%Q3 Operating Expenses$10 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Press Release: ID:nBw9ps2k4aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582388238","isCrawlerRequest":true}